Oncolytic virotherapy for human bone and soft tissue sarcomas using live attenuated poliovirus

International Journal of Oncology

Volumn 41, Issue 3, 2012, Pages 893-902

  Atsumi, Satoru ^a   Matsumine, Akihiko ^a   Toyoda, Hidemi ^a   Niimi, Rui ^a   Iino, Takahiro ^a   Nakamura, Tomoki ^a   Matsubara, Takao ^a   Asanuma, Kunihiro ^a   Komada, Yoshihiro ^a   Uchida, Atsumasa ^a   Sudo, Akihiro ^a  

^a MIE UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

Author keywords

CD155 PVR Necl 5; Oncolytic virotherapy; Osteosarcoma; Poliovirus; Soft tissue sarcoma

Indexed keywords

CASPASE 3; CASPASE 7; CD155 ANTIGEN; LIVE ATTENUATED POLIOVIRUS VACCINE; LYMPHOCYTE ANTIGEN; MESSENGER RNA; POLIOMYELITIS VACCINE; TUMOR PROTEIN; UNCLASSIFIED DRUG;

ANIMAL EXPERIMENT; ANIMAL MODEL; APOPTOSIS; ARTICLE; CANCER CELL CULTURE; CANCER INHIBITION; CELL PROLIFERATION; CONTROLLED STUDY; DRUG EFFICACY; ENZYME ACTIVITY; FEMALE; FIBROSARCOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NICK END LABELING; NONHUMAN; ONCOLYTIC VIROTHERAPY; OSTEOSARCOMA; POLIOMYELITIS VIRUS; PRIORITY JOURNAL; PROTEIN EXPRESSION; SARCOMA CELL; SOFT TISSUE SARCOMA; TUMOR SUPPRESSOR GENE; TUMOR XENOGRAFT; VIRUS STRAIN;

ANIMALS; APOPTOSIS; BONE NEOPLASMS; CASPASE 3; CASPASE 7; CELL LINE, TUMOR; HUMANS; MICE; ONCOLYTIC VIROTHERAPY; ONCOLYTIC VIRUSES; OSTEOSARCOMA; POLIOVIRUS; RECEPTORS, VIRUS; RNA, MESSENGER; SARCOMA; XENOGRAFT MODEL ANTITUMOR ASSAYS;

EID: 84865007679     PISSN: 10196439     EISSN: 17912423     Source Type: Journal    
DOI: 10.3892/ijo.2012.1514     Document Type: Article

References (51)

1. Jemal A, Siegel R, Xu J and Ward E: Cancer statistics. CA Cancer J Clin 60: 277-300, 2010.
2. Billingsley KG, Burt ME, Jara E, Ginsberg RJ, Woodruff JM, Leung DH and Brennan MF: Pulmonary metastases from soft tissue sarcoma: analysis of patterns of diseases and postmetastasis survival. Ann Surg 229: 602-610, 1999.
3. Gilbert NF, Cannon CP, Lin PP and Lewis VO: Soft-tissue sarcoma. J Am Acad Orthop Surg 17: 40-47, 2009.
4. Clark MA, Fisher C, Judson I and Thomas JM: Soft-tissue sarcomas in adults. N Engl J Med 353: 701-711, 2005. (Pubitemid 41175678)
5. Grimer R, Judson I, Peake D and Seddon B: Guidelines for the management of soft tissue sarcomas. Sarcoma: May 31, 2010 (Epub ahead of print). doi: 10.1155/2010/506182.
6. No authors listed: Adjuvant chemotherapy for localised resectable soft-tissue sarcoma of adults: meta-analysis of individual data. Sarcoma Meta-analysis Collaboration. Lancet 350: 1647-1654, 1997.
7. Gortzak E, Azzarelli A, Buesa J, et al: A randomised phase II study on neo-adjuvant chemotherapy for 'high-risk' adult soft-tissue sarcoma. Eur J Cancer 37: 1096-1103, 2001.
8. Sinkovics JG and Horvath JC: New developments in the virus therapy of cancer: a histrogical review. Intervirology 36: 193-214, 1993.
9. Sinkovics JG and Horvath JC: Natural and genetically engineered viral agents for oncolysis and gene therapy of human cancers. Arch Immunol Ther Exp (Warsz) 56 (Suppl 1): 3s-59s, 2008.
10. Parato KA, Senger D, Forsyth PA and Bell JC: Recent progress in the between oncolytic viruses and tumors. Nat Rev Cancer 5: 965-976, 2005. (Pubitemid 41766784)
11. Coffey MC, Storong J E, Forsyth PA a nd L ee PW: Reovirus therapy of tumors with activated Ras pathway. Science 282: 1332-1334, 1998. (Pubitemid 28524498)
12. Sinkovics JG and Horvath JC: Newcastle disease virus (NDV): brief history of its oncolytic strain. J Clin Virol 16: 1-15, 2000. (Pubitemid 30066477)
13. Springfeld C, Fielding AK, Peng KW, Galanis E, Russell SJ and Cattaneo R: Measles virus: improving natural oncolytic properties by genetic engineering. In: Viral Therapy of Human Cancers. Sinkovics JG and Horvath JC (eds). Marcel Dekker Inc., New York, NY, pp459-480, 2005.
14. Stojdl DF, Litchy B, Knowles S, Marius R, Atkins H, Sonenberg N and Bell JC: Exploiting tumor-specific defects in interferon pathway with a previously unknown oncolytic virus. Nat Med 6: 821-825, 2000. (Pubitemid 30469434)
15. Gromeier M, Lachmann S, Rosenfeld MR, Gutin PH and Wimmer E: Intergenic poliovirus recombinants for treatment of malignant glioma. Proc Natl Acad Sci USA 97: 6803-6808, 2000. (Pubitemid 30412795)
16. Bodian D: Poliomyelitis. In: Pathology of the Nervous System. Minckler J (ed). McGraw-Hill, New York, NY, pp2323-2344, 1972.
17. Ren R, Costantini F, Gorgacz EJ, Lee JJ and Racaniello VR: Transgenic mice expressing a human poliovirus receptor: a newmodel for poliomyelitis. Cell 63: 353-362, 1990.
18. Koike S, Taya C, Kurata T, Abe S, Ise I, Yonekawa H and Nomoto A: Transgenic mice susceptible to poliovirus. Proc Natl Acad Sci USA 88: 951-955, 1991. (Pubitemid 21916142)
19. Gromeier M, Alexander L and Wimmer E: Internal ribosomal entry site substitution eliminates neurovirulence in intergenic poliovirus recombinants. Proc Natl Acad Sci USA 93: 2370-2375, 1996. (Pubitemid 26104357)
20. Kauder SE and Racaniello VR: Internal ribosomal entry site substitution eliminates neurovirulence in intergenic poliovirus recombinants. Proc Natl Acad Sci USA 93: 2370-2375, 1996.
21. Takai Y, Miyoshi J, Ikeda W and Ogita H: Nectins and nectin-like molecules: roles in contact inhibition of cell movement and proliferation. Nat Rev Mol Cell Biol 9: 603-615, 2008. (Pubitemid 352032927)
22. Amano H, Ikeda W, Kawano S, et al: Interaction and localization of Necl-5 and PDGF receptor beta at the leading edges of moving NIH3T3 cells: implications for directional cell movement. Genes Cells 13: 269-284, 2008. (Pubitemid 351292282)
23. Merrill MK, Bernhardt G, Sampson JH, Wikstrand CJ, Bigner DD and Gromeier M: Poliovirus receptor CD155-targeted oncolysis of glioma. Neuro Oncol 6: 208-217, 2004. (Pubitemid 39136504)
24. Toyoda H, Hayashi T, Gabbazza EC, et al: Experimental treatment of human neuroblastoma using live-attenuated poliovirus. Int J Oncol 24: 49-58, 2004.
25. Nobis P, Zibirre R, Meyer G, Kuhne J, Warnecke G and Koch G: Production of a monoclonal antibody against an epitope on HeLa cells that is the functional poliovirus binding site. J Gen Virol 66: 2563-2569, 1985. (Pubitemid 16180019)
26. Wakabayashi T, Matsumine A, Nakazora S, et al: Fibulin-3 negatively regulates chondrocyte differentiation. Biochem Biophys Res Commun 391: 1116-1121, 2010.
27. Kono T, Imai Y, Yasuda S, et al: The CD155/poliovirus receptor enhances the proliferation of ras-mutated cells. Int J Cancer 122: 317-324, 2008. (Pubitemid 350234717)
28. Tomayko MM and Reynald CP: Determination of subcutaneous tumor size in athymic (nude) mice. Cance Chemother Pharmacol 24: 148-154, 1989. (Pubitemid 19163397)
29. Mendelsohn CL, Wimmer E and Racaniello VR: Cellular receptor for poliovirus: molecular cloning, nucleotide sequence, and expression of a new member of the immunoglobulin superfamily. Cell 56: 855-865, 1989. (Pubitemid 19082521)
30. Grimer R, Athanasou N, Gerrand C, et al: UK Guidelines for the Management of Bone Sarcomas. Sarcoma: Dec 29, 2010 (Epub ahead of print). doi: 10.1155/2010/317462.
31. Solecki D, Wimmer E, Lipp M and Bernhardt G: Identification and characterization of the cis-acting elements of the human CD155 gene core promoter. J Biol Chem 274: 1791-1800, 1999.
32. Solecki D, Bernhardt G, Lipp M and Wimmer E: Identification of nuclear respiratory factor-1 binding site within the core promoter of polio virus receptor/ CD155 gene. J Biol Chem 275: 12453-12462, 2000. (Pubitemid 30241387)
33. Marsson D, Jarry A, Baury B, Blanchardie P, Laboisse C, Lustenberger P and Denis MG: Overexpression of CD155 gene in human colorectal cartinoma. Gut 49: 236-240, 2001. (Pubitemid 32675118)
34. Solecki DJ, Gromeier M, Mueller S, Bernhardt G and Wimmer E: Expression of the human poliovirus receptor/CD155 gene is activated by sonic hedgehog. J Biol Chem 277: 25697-25702, 2002. (Pubitemid 34951888)
35. Li F, Shi W, Capurro M and Filmus J: Glypican-5 stimulates rhabdomyosarcoma cell proliferation by activating Hedgehog signaling. J Cell Biol 192: 691-704, 2011.
36. Oue T, Yoneda A, Uehara S, Yamanaka H and Fukuzawa M: Increased expression of the hedgehog signaling pathway in pediatric solid malignancies. J Pediatr Surg 45: 387-392, 2010.
37. Minami Y, Ikeda W, Kajita M, Fujito T, Monden M and Takai Y: Involvement of up-regulated Necl-5/Tage4/PVR/CD155 in the loss of contact inhibition in transformed NIH3T3 cells. Biochem Biophys Res Commun 352: 856-860, 2007. (Pubitemid 44894364)
38. Toyoda H, Franco D, Fujita K, Paul AV and Wimmer E: Replication of poliovirus requires binding of the poly(rC) binding protein to cloverleaf as well as to the adjacent C-rich spacer sequence between the cloverleaf and the internal ribosomal entry site. J Virol 81: 10017-10028, 2007. (Pubitemid 350067705)
39. Gosselin AS, Simonin Y, Guivel-Benhassine F, et al: Poliovirus-induced apoptosis is reduced in cell expressing a mutant CD155 selected during presistant poliovirus infection in neuroblastoma cells. J Virol 77: 790-798, 2003. (Pubitemid 36005021)
40. Whitton JL, Cornell CT and Feuer R: Host and virus determinants of picornavirus pathogenesis and tropism. Nat Rev Microbiol 3: 765-776, 2005. (Pubitemid 41518737)
41. Ida-Hosonuma M, Iwasaki T, Yoshikawa T, et al: The alpha/beta interferon response controls tissue tropism and pathogenicity of poliovirus. J Virol 79: 4460-4469, 2005. (Pubitemid 40388383)
42. Melnick JL: Enteroviruses: polioviruses, coxsackieviruses, echoviruses, and newer enteroviruses. In: Virology. Fields BN, Knipe DM, Howley PM, et al (eds). Raven Press, New York, NY, pp549-605, 1995.
43. Yang WX, Terasaki T, Shiroki K, et al: Efficient delivery of circulating poliovirus to the central nervous system independently of poliovirus receptor. Virology 229: 421-428, 1997. (Pubitemid 27241091)
44. Strebel PM, Ion-Nedelcu N, Baughman AL, Sutter RM and Cochi SL: Intramuscular injections within 30 days of immunization with oral poliovirus vaccine - a risk factor for vaccine-associated paralytic poliomyelitis. N Engl J Med 332: 500-506, 1995.
45. Ohka S, Matsuda N, Tohyama K, Oda T, Morikawa M, Kuge S and Nomoto A: Receptor(CD155)-dependent endocytosis of poliovirus and retrograde axonal transport of the endosome. J Virol 78: 7186-7198, 2004. (Pubitemid 38781557)
46. Gromeier M and Wimmer E: Mechanism of injury-provoked poliomyelitis. J Virol 72: 5056-5060, 1998. (Pubitemid 28215685)
47. Ochs K, Zeller A, Saleh L, Bassili G, Song Y, Sonntag A and Niepmann M: Impaired binding of standard initiation factors mediates poliovirus transla tion attenuation. J Virol 77: 115-122, 2003. (Pubitemid 36007798)
48. Toyoda H, Yin J, Mueller S, Wimmer E and Cello J: Oncolytic treatment and care of neuroblastoma by a novel attenuated poliovirus in a novel poliovirus-susceptible animal model. Cancer Res 67: 2857-2864, 2007. (Pubitemid 46548976)
49. Porosnicu M, Mian A and Barber GN: The oncolytic effect of recombinant vesicular stomatitis virus in enhanced by expression of the fusion cytosine deaminase/uracil phosphoribosyltransferase suicide gene. Cancer Res 63: 8366-8376, 2003. (Pubitemid 37549491)
50. Obuchi M, Fernandez M and Barber GN: Development of recombinant vesicular stomatitis virus that exploit defects in host defense to augment specific oncolytic activity. J Virol 77: 8843-8856, 2003. (Pubitemid 36936096)
51. Pavio N, Couderc T, Girard S, Sgro JY, Blondel B and Colbère- Garapin F: Expression of mutated poliovirus receptors in human neuroblastoma cells persistently infected with poliovirus. Virology 274: 331-342, 2000.